Oncology Nurse Edition Advertising

A total of 30.0% and 31.5% of families with children undergoing chemotherapy for ALL experienced household material hardship or catastrophic income loss.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Future work may expand analyses of measurable residual disease as a surrogate end point in AML to the use of modern, non-intensive treatment backbones.

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.